A Current Review of Folate Receptor Alpha As a Potential Tumor Target in Non-small-cell Lung Cancer

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2015 Sep 11

PMID 26357465

Citations 42

Authors

Huan Shi

Jun Guo

Changzheng Li

Zhehai Wang

Affiliations

Soon will be listed here.

Abstract

Lung cancer remains the leading common cause of cancer-related death, with non-small-cell lung cancer (NSCLC) accounting for 80% of all cases. To date, platinum-based doublet chemotherapy is the cornerstone of first-line therapy. However, these agents have limited use in patients who have relapsed and have metastatic disease. Therefore, novel strategies are required to improve the clinical outcome. Folate receptor alpha (FRA) is overexpressed in the majority of NSCLC, particularly in lung adenocarcinomas. FRA is largely absent from normal tissue, making it an attractive therapeutic target. In this review, we discuss FRA expression in NSCLC, conjugated FRA agents, monoclonal antibody, and FRA-specific T-cell-based therapeutic strategies aiming to improve the cure rate of FRA-expressing NSCLC.

Citing Articles

Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?.

Bukowski K, Rogalska A, Marczak A Int J Mol Sci. 2024; 25(22).

PMID: 39595996 PMC: 11593442. DOI: 10.3390/ijms252211927.

Prospects for Fluorescence Molecular Liquid Biopsy of Circulating Tumor Cells in Humans.

Niedre M Front Photon. 2024; 3.

PMID: 39508030 PMC: 11540420. DOI: 10.3389/fphot.2022.910035.

Unveiling the Therapeutic Potential of Folate-Dependent One-Carbon Metabolism in Cancer and Neurodegeneration.

Sobral A, Cunha A, Silva V, Gil-Martins E, Silva R, Barbosa D Int J Mol Sci. 2024; 25(17).

PMID: 39273288 PMC: 11395277. DOI: 10.3390/ijms25179339.

Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers.

Khadela A, Megha K, Shah V, Soni S, Shah A, Mistry H Clin Med Insights Oncol. 2024; 18:11795549241260534.

PMID: 38911453 PMC: 11193349. DOI: 10.1177/11795549241260534.

Moving beyond traditional therapies: the role of nanomedicines in lung cancer.

Zhang J, Li Y, Guo S, Zhang W, Fang B, Wang S Front Pharmacol. 2024; 15:1363346.

PMID: 38389925 PMC: 10883231. DOI: 10.3389/fphar.2024.1363346.

References

Hartmann L, Keeney G, Lingle W, Christianson T, Varghese B, Hillman D . Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 2007; 121(5):938-42. DOI: 10.1002/ijc.22811. View

Garin-Chesa P, Campbell I, Saigo P, Lewis Jr J, Old L, Rettig W . Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol. 1993; 142(2):557-67. PMC: 1886733. View

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

Liu L, Sun M, Wang Z . Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors. Cancer Lett. 2011; 316(1):1-5. DOI: 10.1016/j.canlet.2011.10.027. View

Edelman M, Harb W, Pal S, Boccia R, Kraut M, Bonomi P . Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012; 7(10):1618-21. DOI: 10.1097/JTO.0b013e318267d051. View

Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M . Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997; 74(2):193-8. DOI: 10.1002/(sici)1097-0215(19970422)74:2<193::aid-ijc10>3.0.co;2-f. View

OShannessy D, Gustavson M, Chandrasekaran L, Dolled-Filhart M, Somers E . Prognostic significance of FRA expression in epithelial cancers using AQUA(®) technology. Biomark Med. 2013; 7(6):933-46. DOI: 10.2217/bmm.13.85. View

Heslop H . Safer CARS. Mol Ther. 2010; 18(4):661-2. PMC: 2862533. DOI: 10.1038/mt.2010.42. View

Allard J, Risinger J, Morrison C, Young G, Rose G, Fowler J . Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol. 2007; 107(1):52-7. DOI: 10.1016/j.ygyno.2007.05.018. View

10.

Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C . Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-51. DOI: 10.1200/JCO.2007.15.0375. View

11.

OShannessy D, Yu G, Smale R, Fu Y, Singhal S, Thiel R . Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012; 3(4):414-425. PMC: 3380576. DOI: 10.18632/oncotarget.519. View

12.

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

13.

Beatty G, Haas A, Maus M, Torigian D, Soulen M, Plesa G . Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014; 2(2):112-20. PMC: 3932715. DOI: 10.1158/2326-6066.CIR-13-0170. View

14.

Li J, Sausville E, Klein P, Morgenstern D, Leamon C, Messmann R . Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol. 2009; 49(12):1467-76. PMC: 3807256. DOI: 10.1177/0091270009339740. View

15.

Kamen B, Smith A . Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol. 2012; 70(1):113-20. DOI: 10.1007/s00280-012-1890-2. View

16.

Zhao X, Li H, Lee R . Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008; 5(3):309-19. DOI: 10.1517/17425247.5.3.309. View

17.

Kane M . The role of folates in squamous cell carcinoma of the head and neck. Cancer Detect Prev. 2005; 29(1):46-53. DOI: 10.1016/j.cdp.2004.08.002. View

18.

Perez-Moreno M, Galvan-Banqueri M, Flores-Moreno S, Villalba-Moreno A, Cotrina-Luque J, Bautista-Paloma F . Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer. Int J Clin Pharm. 2014; 36(3):476-87. DOI: 10.1007/s11096-014-9920-2. View

19.

Zhao Y, Moon E, Carpenito C, Paulos C, Liu X, Brennan A . Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010; 70(22):9053-61. PMC: 2982929. DOI: 10.1158/0008-5472.CAN-10-2880. View

20.

Konner J, Bell-McGuinn K, Sabbatini P, Hensley M, Tew W, Pandit-Taskar N . Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010; 16(21):5288-95. DOI: 10.1158/1078-0432.CCR-10-0700. View